Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Thermo Fisher Scientific heads into its October 21 print with options positioning leaning more constructive than usual, short interest near low levels, and the stock trading up to $690 after a 5% weekly gain.
Options traders are less defensive than their recent posture suggests. The put/call ratio has dropped to 0.79, roughly one standard deviation below its 20-day average of 0.83. That shift toward calls rather than puts marks a departure from the more cautious tone seen through most of September and early October. The 52-week PCR range runs from 0.51 to 2.27, so current positioning is not extreme, but the direction of travel ahead of a print is notable. Meanwhile, short interest is a minor factor in this setup. At 1.37% of the free float, with shares borrowed falling slightly over the past week, there is no meaningful bearish crowding in the lending market. Borrow availability is essentially unlimited, and cost-to-borrow has eased to 0.33%, down roughly 30% over the past month, reinforcing how little demand there is to short this name.
The bullish case heading into the print rests on a pronounced re-rating of Street targets. Since October 7, Barclays, Morgan Stanley, and TD Cowen have all raised price targets, with Morgan Stanley moving from $650 to $730 and Barclays from $650 to $750. The consensus mean has moved up to $690.62, sitting almost exactly at the current share price. As the previous ORTEX note on this stock observed, the direction of that re-rating matters more than the gap to the target: as recently as late July, most major firms were clustered around $620 to $650. Bears point to a more structural concern. Adjusted EBIT margins have fallen roughly 830 basis points since 2021 to around 22.6%, and gross margins remain well below the company's 2019 peak. Biotech funding has also been a headwind, with capital raised in the sector running well below prior-year levels. Piper Sandler and RBC both sit at neutral-equivalent ratings with targets of $600 and $580 respectively, both from late July, a reminder that not everyone is aligned with the recent bull tide.
The most recent earnings print, in July, produced a one-day gain of nearly 8% and a five-day follow-through of around 9.5%, a reaction that appears to have emboldened the target increases now on the table. Retail attention is also running above its own 90-day baseline, with the Wikipedia views signal from Wikimedia Foundation registering a z-score of 1.43 as of late September, a secondary signal worth noting given the stock's broader visibility rather than any link to reported revenues.
The October 21 print is therefore less about whether Thermo Fisher is growing and more about whether management can show the margin trajectory stabilising at a pace that justifies a share price now sitting right at the upgraded consensus.
See the live data behind this article on ORTEX.
Open TMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
